PACIRA BIOSCIENCES, INC. Shareholders' Equity
PACIRA BIOSCIENCES, INC. (PCRX) had Shareholders' Equity of $671.98 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $671.98M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $653.89M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $693.11M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $727.21M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $671.98M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $653.89M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $693.11M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $727.21M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $757.77M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $798.54M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $778.35M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $749.58M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $879.28M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $892.16M 10-Q · filed 2025-08-05 | |
| 2023-12-31 | $870.13M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $831.55M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $807.98M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $768.04M 10-Q · filed 2024-07-30 | |
| 2022-12-31 | $775.01M 10-K · filed 2026-02-26 | |
| 2022-09-30 | $770.12M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $756.64M 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $709.58M 10-Q · filed 2023-08-02 | |
| 2021-12-31 | $730.41M 10-K · filed 2025-02-27 | |
| 2021-09-30 | $718.60M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $687.17M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $650.82M 10-Q · filed 2022-08-03 | |
| 2020-12-31 | $619.69M 10-K · filed 2024-02-29 | |
| 2020-09-30 | $584.69M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $388.15M 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $374.04M 10-Q · filed 2021-08-03 | $374.04M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $354.94M 10-K · filed 2023-02-28 | |
| 2019-09-30 | $346.16M 10-Q · filed 2020-10-30 | |
| 2019-06-30 | $341.65M 10-Q · filed 2020-10-30 | |
| 2019-03-31 | $327.52M 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $321.23M 10-K · filed 2022-02-28 | |
| 2018-09-30 | $301.27M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $290.51M 10-Q · filed 2019-11-08 | |
| 2018-03-31 | $278.52M 10-Q · filed 2019-08-08 | |
| 2017-12-31 | $279.48M 10-K · filed 2021-03-01 | |
| 2017-09-30 | $264.80M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $261.05M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $270.63M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $218.98M 10-K · filed 2020-02-21 | |
| 2016-09-30 | $214.15M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $228.35M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $226.17M 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $218.39M 10-K · filed 2019-02-28 | |
| 2015-09-30 | $209.01M 10-Q · filed 2015-10-27 | |
| 2015-06-30 | $195.28M 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $184.02M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $171.15M 10-K · filed 2018-02-28 | |
| 2014-09-30 | $155.07M 10-Q · filed 2014-10-30 | |
| 2014-06-30 | $147.97M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $35.71M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $41.25M 10-K · filed 2017-03-01 | |
| 2013-09-30 | $49.12M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $59.14M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $69.79M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $65.86M 10-K · filed 2016-02-25 | |
| 2012-09-30 | $80.44M 10-Q · filed 2012-11-01 | |
| 2012-06-30 | $94.50M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $37.24M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | $48.27M 10-K · filed 2015-02-24 | |
| 2011-09-30 | $13.88M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $22.93M 10-Q · filed 2011-08-11 | |
| 2010-12-31 | -$48.38M 10-K · filed 2014-02-25 | |
| 2009-12-31 | -$22.95M 10-K · filed 2013-03-07 | |
| 2008-12-31 | $7.49M 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |